Scientific Publications

In Vitro Differentiation of Two FDA-Approved Abuse-Deterrent Opioids’ Resistance to Oral Mastication - PAINWeek 2017 and AAPS 2017In vitro study evaluating the resistance to chewing of an ADF with oral mastication claims relative to another ADF with physical, chemical, and injection claims but, without oral mastication claims. A non–abuse-deterrent commercial product (non-ADF) was included as a control. Abuse-Deterrent Technologies: One Step in the Opioid Epidemic but, How do we Evaluate Them? Chris Altomare from DRUGSCAN discusses in vitro laboratory experiments that are designed to simulate prescription drug abuser techniques in the evaluation abuse-deterrent formulations – AAPS Blog January 2017 Exploratory In Vitro Laboratory Study to Assess Potential Abuse-Deterrent Features of Polyethylene Oxide Extended Release Matrices – AAPS 2016 An exploratory in vitro study assessing the syringe-ability, sniff-ability, extractability and the ability to rectally administer two abuse-deterrent formulations of POLYOX (polyethylene oxide) extended release tablets versus a comparator with no abuse-deterrent features In Vitro Test Characterization of an Immediate Release Product with Abuse Deterrent Features – AAPS 2016 In vitro physical manipulation, syringe-ability, extraction and API isolation studies to characterize the abuse-deterrent properties of an immediate release hydrocodone-acetaminophen tablet compared to a marketed product with no abuse-deterrent features Optimization of a Smoking-Simulation Technique to Investigate Smoke-Ability of Opioids from Pharmaceutical Formulations – PAINWeek 2016 Optimization of a proprietary apparatus that simulates smoking in vitro using two commonly abused opioids Extreme Work Requirement of EG-001, an Abuse-Deterrent, Extended-Release Morphine Product, as Demonstrated with the ALERRT℠ Visual Analog Scales– PAINWeek 2015 Measure the amount of time, effort, and resources required to physically compromise an abuse-deterrent extended release morphine compared to marketed extended release and immediate release morphine products using a novel visual analog scale EG-002, a Novel Proprietary Abuse-Deterrent, Extended-Release Formulation of Oxycodone, Demonstrates Strong Abuse-Deterrent Potential Based on the Results from a Category 1 In Vitro Physical Manipulation Study – PAINWeek 2015 Single-step physical manipulation studies to evaluate the abuse-deterrent properties of an investigational extended release oxycodone tablet in comparison with a marketed abuse-deterrent extended release oxycodone formulation